id: NEW:gabapentin_treatment_aws_to_alcohol_withdrawal_severe_rate
name: Gabapentin Treatment for Acute Alcohol Withdrawal Syndrome â†’ Alcohol Withdrawal
  Severe Rate
from_node:
  node_id: NEW:gabapentin_treatment_aws
  node_name: Gabapentin Treatment for Acute Alcohol Withdrawal Syndrome
to_node:
  node_id: alcohol_withdrawal_severe_rate
  node_name: Alcohol Withdrawal Severe Rate
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Gabapentin is administered to hospitalized patients experiencing acute
  alcohol withdrawal syndrome (AWS), often as adjunctive therapy alongside benzodiazepines'
- 'Step 2: Gabapentin''s mechanism of action modulates GABA activity and calcium channels,
  potentially reducing neuronal hyperexcitability characteristic of alcohol withdrawal'
- 'Step 3: In patients with severe AWS, gabapentin treatment is associated with reduced
  benzodiazepine requirements, suggesting improved symptom control'
- 'Step 4: Faster symptom resolution rate in gabapentin-treated patients may prevent
  progression to severe withdrawal complications such as seizures and delirium tremens'
- 'Step 5: Reduced hospital length of stay in severe AWS subgroup indicates more efficient
  symptom management and reduced severity of withdrawal episodes'
evidence:
  quality_rating: B
  n_studies: 8
  primary_citation: 'Anna G Mattle et al. 2022. Gabapentin to treat acute alcohol
    withdrawal in hospitalized patients: A systematic review and meta-analysis. Drug
    and alcohol dependence.'
  supporting_citations: []
description: Gabapentin treatment for acute alcohol withdrawal syndrome shows potential
  for reducing severe withdrawal outcomes, particularly in patients with severe AWS.
  The meta-analysis of 8 retrospective studies (n=2030) found significant improvements
  in symptom resolution rate favoring gabapentin. Subgroup analyses revealed that
  severe AWS patients receiving gabapentin had reduced hospital length of stay and
  lower benzodiazepine requirements, suggesting gabapentin may help prevent progression
  to severe withdrawal complications.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
moderators:
- name: Baseline AWS severity
  direction: strengthens
  strength: moderate
  description: Subgroup analysis of severe AWS patients showed significant improvements
    in LOS (p=0.04) and reduced benzodiazepine use (p=0.02), though based on limited
    studies
- name: Concurrent benzodiazepine use
  direction: weakens
  strength: moderate
  description: Patients receiving gabapentin alone without benzodiazepines showed
    significantly decreased LOS compared to benzodiazepine-only group (p<0.001)
